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BSTRACT
 
Background
 
Previous studies have suggested
that the use of nonsteroidal antiinflammatory drugs
(NSAIDs) may help to prevent Alzheimer’s disease.
The results, however, have been inconsistent.
 
Methods
 
We studied the association between the
use of NSAIDs and Alzheimer’s disease and vascular
dementia in a prospective, population-based cohort
study of 6989 subjects 55 years of age or older who
were free of dementia at base line. The risk of Alzhei-
mer’s disease was estimated in relation to the use of
NSAIDs as documented in pharmacy records. We de-
fined four mutually exclusive categories of use: non-
use, short-term use (1 month or less of cumulative
use), intermediate-term use (more than 1 but less
than 24 months of cumulative use), and long-term use
(24 months or more of cumulative use). Adjustments
were made by Cox regression analysis for age, sex,
education, smoking status, and the use or nonuse of
salicylates, histamine H
 
2
 
-receptor antagonists, antihy-
pertensive agents, and hypoglycemic agents.
 
Results
 
During an average follow-up period of 6.8
years, dementia developed in 394 subjects, of whom
293 had Alzheimer’s disease, 56 vascular dementia,
and 45 other types of dementia. The relative risk of
Alzheimer’s disease was 0.95 (95 percent confidence
interval, 0.70 to 1.29) in subjects with short-term use
of NSAIDs, 0.83 (95 percent confidence interval, 0.62
to 1.11) in those with intermediate-term use, and 0.20
(95 percent confidence interval, 0.05 to 0.83) in those
with long-term use. The risk did not vary according to
age. The use of NSAIDs was not associated with a re-
duction in the risk of vascular dementia.
 
Conclusions
 
The long-term use of NSAIDs may
protect against Alzheimer’s disease but not against
vascular dementia. (N Engl J Med 2001;345:1515-21.)
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HE neuropathologic features of Alzheimer’s
disease include the accumulation of micro-
glia around plaques, a local cytokine-medi-
ated acute-phase response, and activation of
the complement cascade.
 
1,2
 
 This inflammatory re-
sponse may damage neurons and exacerbate the patho-
logic processes underlying the disease.
 
3
 
 Nonsteroidal
antiinflammatory drugs (NSAIDs) may influence this
inflammatory response by inhibiting cyclooxygen-
ase-1 and cyclooxygenase-2 and by activating the per-
oxisome proliferator 
 
g
 
 (PPAR
 
g
 
) nuclear transcription
factor.
 
4-6
 
 In addition, cyclooxygenase-mediated oxida-
tion is important in the calcium-dependent glutamate-
signaling pathway that involves 
 
N
 
-methyl-
 
D
 
-aspartate.
In this way, NSAIDs may be able to protect neurons
directly by reducing cellular responses to glutamate.
 
7
 
The results of observational studies have been in-
consistent with regard to the association between
NSAIDs and Alzheimer’s disease.
 
8-30
 
 Some have sug-
gested a protective effect, whereas others have not. In
almost all the studies, information on NSAIDs was ob-
tained retrospectively from patients or relatives or from
medical records. These methods are vulnerable to mis-
classification of drug exposure. In the Netherlands,
computerized pharmacy records are virtually complete
sources of information on the delivery of drugs. We
conducted a prospective, population-based cohort
study to determine whether the use of NSAIDs other
than aspirin was associated with a decreased risk of
Alzheimer’s disease or vascular dementia.
T
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METHODS
 
Study Population
 
The Rotterdam Study is a prospective, population-based co-
hort study of neurologic, cardiovascular, locomotor, and ophthal-
mologic diseases in elderly persons.
 
31
 
 In brief, all persons 55 years
of age or older who were living in Ommoord, a suburb of Rot-
terdam, the Netherlands, were invited to participate in the study
between 1990 and 1993. Of the 10,275 eligible subjects, 7983
(78 percent) gave written informed consent to participate. They
were interviewed at home by trained interviewers on a wide range
of topics, including socioeconomic background, medical history,
and medication use. During subsequent visits to the research center,
the subjects underwent additional interviews and examinations, in-
cluding screening and clinical workup for dementia. In addition,
apolipoprotein E genotyping was performed on coded DNA sam-
ples by investigators who were unaware of whether the subjects had
dementia.
 
32
 
 Nearly all the participants (99.7 percent) were regis-
tered at one or more of the seven pharmacies serving the Om-
moord area. These pharmacies are fully automated, and all record-
ed data on drug use during the period from January 1, 1991,
through December 31, 1998.
The potential study period consisted of the eight-year period
from January 1, 1991, through December 31, 1998. Of the 7983
subjects who had agreed to participate, 7528 (94.3 percent) were
screened and examined for dementia,
 
33,34
 
 and 7046 were found
to be free of dementia at base line. From this group, we excluded
the 57 subjects for whom follow-up ended before July 1, 1991,
because there was less than six months of data on their history of
medication use. Participants were then screened again for dementia
at a second examination (during 1993 or 1994) and at a third ex-
amination (during 1997, 1998, or 1999), as described below. Every
member of the final study population of 6989 subjects was followed
until the occurrence of death, a diagnosis of dementia, or the end
of the study period, which was the date of the last examination
unless this examination was performed in 1999, in which case the
end of the study period was defined as December 31, 1998.
 
Information on the Use of NSAIDs and Other Drugs
 
Complete information on prescriptions was available in automat-
ed form and included the product name; the international nonpro-
prietary name of the drug; the number of tablets, capsules, or other
vehicle in the filled prescription; the date of delivery of the prod-
uct; the prescribed daily number of tablets to be taken; the drug
dosage; and the duration of the prescription period. For compar-
isons of dosages, we used the “defined daily dose,” which is the
average dosage of a drug taken by adults for the main indication,
according to the World Health Organization.
 
35
 
 All prescriptions
for oral NSAIDs filled during follow-up were used to create time-
dependent covariates, as described below. Because oral salicylate-
based analgesics, including the platelet-inhibiting salicylates acetyl-
salicylic acid (aspirin) and carbaspirin calcium, are pharmacologically
related to NSAIDs, separate time-dependent covariates were also
created for these drugs so that we could study their association with
Alzheimer’s disease.
 
Ascertainment of Dementia
 
Both at the base-line examination and at follow-up examinations,
the subjects were examined for dementia according to a three-
step protocol.
 
33,34
 
 First, subjects were screened with the use of the
Mini–Mental State Examination (on which possible scores range
from 0 to 30, with lower scores indicating worse cognitive func-
tion)
 
36
 
 and the Geriatric Mental State Schedule (organic level [a
subquestionnaire used to screen for an organic syndrome]) (where
possible scores range from 0 to 5, with higher scores indicating a
higher probability of dementia).
 
37
 
 Second, those scoring 25 or be-
low on the Mini–Mental State Examination or scoring 1 or more
on the Geriatric Mental State Schedule were selected for further di-
agnostic evaluation and were subsequently examined by a physi-
cian using the Cambridge Mental Disorders of the Elderly Exam-
ination diagnostic interview.
 
38
 
 Third, subjects who were believed to
have dementia were examined by a neurologist and a neuropsychol-
ogist and underwent magnetic resonance imaging of the brain.
In addition to undergoing screening for dementia, the subjects
were continuously monitored for cases of dementia during follow-
up.
 
33
 
 A clinical diagnosis of dementia was made according to the
criteria of the 
 
Diagnostic and Statistical Manual of Mental Disor-
ders,
 
 third edition, revised, by a panel that reviewed all existing
information. A subdiagnosis of Alzheimer’s disease was made ac-
cording to the criteria of the National Institute of Neurological and
Communicative Diseases and Stroke–Alzheimer’s Disease and Re-
lated Disorders Association.
 
39
 
 A subdiagnosis of vascular dementia
was made according to the criteria of the National Institute of Neu-
rological Disorders and Stroke–Association Internationale pour la
Recherche et l’Enseignement en Neurosciences.
 
40
 
 The date of on-
set of dementia was defined as the date midway between the date
of the last examination at which the subject was deemed to be free
of dementia and the date of the examination at which he or she
was given a diagnosis of dementia.
 
Statistical Analysis
 
For every subject in the cohort, we calculated the person-time
between January 1, 1991, and death, a diagnosis of dementia, or the
end of the study period, whichever came first. We calculated the
relative risks of dementia (and 95 percent confidence intervals) with
the use of a Cox proportional-hazards model
 
41
 
; the cumulative use
of each drug was represented by a time-dependent covariate. In the
Cox model, age in days was used as the time axis to ensure opti-
mal adjustment for age.
 
42
 
 We used SAS software (PHREG proce-
dure, version 6.12, SAS Institute, Cary, N.C.) to estimate the age-
specific incidence of Alzheimer’s disease and vascular dementia in
relation to the use of NSAIDs.
Apart from a time-dependent comparison in which any use was
compared with no use, we created time-dependent categorical var-
iables by dividing the cumulative use of NSAIDs during the study
period into four mutually exclusive categories: nonuse, short-
term use (1 month or less of cumulative use), intermediate-term
use (more than 1 but less than 24 months of cumulative use), and
long-term use (24 months or more of cumulative use). These cut-
off points were chosen to ensure an adequate number of subjects
in each group and are similar to those used in a previous, long-term
prospective study.
 
26
 
 The four time-dependent categorical variables
with respect to cumulative exposure times were represented in the
models by three dummy variables, with nonuse as the reference
category. In this model, a cohort member could contribute person-
time to more than one category of cumulative exposure. To adjust
for the loss of information by the categorization of duration, we
also modeled the relation between cumulative duration and effect
by using quadratic spline regression.
 
43
 
 In addition, in this analysis,
we examined the effect on the relative risks of a lag time
 
26,44-46
 
 by
excluding either the last year or the last two years before diagnosis.
In this way, we dealt with potential protopathic bias that might
be caused by changes in the use of NSAIDs during the prodromal
phase of dementia. In addition, we performed a test for trend for
each of the three splines. In a similar manner, time-dependent cat-
egorical variables were constructed with respect to the cumulative
duration of use of aspirin and of related oral salicylates.
Potential confounding variables included sex, age (as defined
above), level of education, smoking status, duration of use of hypo-
glycemic agents (as a proxy for the duration of diabetes mellitus),
and treatment with histamine H
 
2
 
-receptor antagonists and antihy-
pertensive agents, which have been reported to be associated with
dementia in previous studies. We also investigated whether there was
an association between the use of corticosteroids or nonnarcotic
analgesic agents and dementia. To study a possible dose–effect re-
lation with respect to NSAIDs, we dichotomized dosage around
the median («1 vs. >1 defined daily dose per day). In additional
analyses, we examined whether age and the presence of the apo-
lipoprotein E 
 
e
 
4 allele modified the effect of NSAIDs on the risk of
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Alzheimer’s disease. Finally, in a subanalysis, we examined wheth-
er prior use of estrogen influenced this risk among the female
subjects.
 
RESULTS
 
During a total of 47,498 person-years of follow-
up, with a mean follow-up time of 6.8 years per sub-
ject, 394 subjects received a diagnosis of dementia.
Of these patients, 293 had Alzheimer’s disease, 56
vascular dementia, and 45 other types of dementia.
Characteristics of the study population are given in
Table 1. Diclofenac, ibuprofen, and naproxen togeth-
er accounted for approximately 83 percent of the to-
tal number of prescriptions for NSAIDs (Table 2).
A greater proportion of the subjects with less than six
years of education than of those with six or more years
of education took NSAIDs during follow-up (66 per-
cent vs. 60 percent). The yearly rate of use was remark-
ably constant over time, with 37 to 40 days of use
per 1000 person-days during the 8 years of follow-up;
the mean duration of a prescription varied between
26.3 and 31.4 days. The total number of NSAID pre-
scriptions during the follow-up period was 23,685.
The average daily number of medicines used by sub-
jects with dementia was 2.7, as compared with 1.9 in
those without dementia (P<0.001). In total, 2314
subjects (33.1 percent) had used aspirin or related
oral salicylates, almost invariably in doses that inhibit
platelets but do not have antiinflammatory activity
(<300 mg per day).
Use of an NSAID at any time, defined as a binary,
time-dependent variable and compared with no use
at any time, was associated with a lower risk of Alz-
heimer’s disease (relative risk, 0.86; 95 percent confi-
dence interval, 0.66 to 1.09). Relative to the risk in
those who did not use NSAIDs, the risk of Alzhei-
mer’s disease was 0.95 (95 percent confidence inter-
val, 0.70 to 1.29) in those whose cumulative NSAID
use was categorized as short-term use, 0.83 (95 per-
cent confidence interval, 0.62 to 1.11) in those with
intermediate-term use, and 0.20 (95 percent confi-
dence interval, 0.05 to 0.83) in those with long-term
use. These risk reductions could not be attributed to
the use of a particular NSAID. No association was
found between the use of NSAIDs and the risk of
 
*Because of rounding, not all percentages total 100. CI denotes confidence interval.
†Patients with this characteristic served as the reference group.
‡A low level of education was defined as a primary education only or low-level vocational training;
a high level was defined as intermediate-level vocational training or a university education.
§Joint symptoms were defined as those that had occurred within one month before the base-line
interview.
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(N=6989)
P
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(N=47,498)
S
 
UBJECTS
 
 
 
WITH
 
D
 
EMENTIA
 
(N=394)
C
 
RUDE
 
 R
 
ELATIVE
 
 R
 
ISK
 
(95% CI)
 
number (percent)
 
Sex
Male† 2795 (40.0) 19,014 (40.0) 125 (31.7) 1.00
Female 4194 (60.0) 28,484 (60.0) 269 (68.3) 1.43 (1.16–1.77)
Educational level‡
Low† 4407 (63.1) 29,635 (62.4) 271 (68.8) 1.00
High 2379 (34.0) 16,834 (35.4) 82 (20.8) 0.53 (0.42–0.68)
No data 203 (2.9) 1,029 (2.2) 41 (10.4) —
Age
«65 yr† 3162 (45.2) 23,485 (49.4) 25 (6.3) 1.00
66–75 yr 2323 (33.2) 15,776 (33.2) 127 (32.2) 6.62 (4.15–10.56)
>75 yr 1504 (21.5) 8,237 (17.3) 242 (61.4) 29.59 (19.0–46.2)
Reason for NSAID use
Rheumatoid arthritis 236 (3.4) 1,518 (3.2) 17 (4.3) 1.37 (0.84–2.22)
Osteoarthritis 1647 (23.6) 11,449 (24.1) 89 (22.6) 0.92 (0.73–1.16)
Joint symptoms§ 3487 (49.9) 23,999 (50.5) 179 (45.4) 0.97 (0.79–1.20)
Apolipoprotein E genotype
 
e
 
2/
 
e
 
2 or 
 
e
 
2/
 
e
 
3† 880 (12.6) 6,146 (12.9) 27 (6.9) 1.00
 
e
 
3/
 
e
 
3 3780 (54.1) 26,027 (54.8) 166 (42.1) 1.46 (0.97–2.19)
 
e
 
2/
 
e
 
4, 
 
e
 
3/
 
e
 
4, or 
 
e
 
4/
 
e
 
4 1793 (25.7) 12,240 (25.8) 152 (38.6) 2.84 (1.89–4.27)
No data 536 (7.7) 3,085 (6.5) 49 (12.4) —
Smoking
Current† 1558 (22.3) 10,617 (22.4) 66 (16.8) 1.00
Previous 2834 (40.5) 19,582 (41.2) 126 (32.0) 1.04 (0.77–1.40)
Never 2430 (34.8) 16,422 (34.6) 174 (44.2) 1.72 (1.29–2.28)
No data 167 (2.4) 877 (1.8) 28 (7.1) —
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vascular dementia (Table 3). In subjects who took
oral salicylates, we found no association between these
drugs and the risk of Alzheimer’s disease, but this
group did have an increased risk of vascular dementia,
which increased with the duration of use (Table 3).
As Figure 1 shows, there was a gradual decline in the
relative risk of Alzheimer’s disease with increasing du-
ration of NSAID use. This trend became more prom-
inent when lag times of one and two years were tak-
en into account in the analyses.
To investigate whether subjects who had normal
cognitive function at base line (1991) but in whom
Alzheimer’s disease developed five or more years lat-
er (in 1995 through 1998) were already taking fewer
NSAIDs than other subjects in 1991, we stratified the
new cases of Alzheimer’s disease into those diagnosed
during the period from 1991 through 1994 and those
diagnosed during the period from 1995 through
1998. For the period from 1991 through 1994, the
crude relative risk of Alzheimer’s disease in aspirin
users was 1.17 (95 percent confidence interval, 0.85 to
1.62), and for the period from 1995 through 1998,
the crude relative risk was 0.72 (95 percent confidence
interval, 0.51 to 1.02). Of those with long-term cu-
mulative use of NSAIDs, 86 percent were already tak-
ing these drugs at base line. Of those with intermedi-
ate-term use, 51 percent were taking NSAIDs at base
line, and of those with short-term use, 20 percent
were doing so at base line.
 
*Because of rounding, not all percentages total 100.
 
T
 
ABLE
 
 2.
 
 U
 
SE OF NSAIDS BY THE STUDY COHORT 
DURING THE EIGHT-YEAR STUDY PERIOD (1991 TO 1998).*
NSAID
PRESCRIPTIONS
(N=23,685)
CUMULATIVE
DURATION
(N=666,903)
DEFINED
DAILY DOSE
no. (% of total) days (% of total) mg
Diclofenac 10,235 (43.21) 239,410 (35.90) 100
Ibuprofen 5,114 (21.59) 140,608 (21.08) 1200
Naproxen 4,177 (17.64) 109,760 (16.46) 500
Piroxicam 1,579 (6.67) 65,564 (9.83) 20
Indomethacin 1,099 (4.64) 47,409 (7.11) 100
Ketoprofen 592 (2.50) 27,385 (4.11) 150
Nabumetone 309 (1.30) 12,736 (1.91) 1000
Apazone 222 (0.94) 6,060 (0.91) 750
Sulindac 127 (0.54) 5,896 (0.88) 400
Meloxicam 75 (0.32) 2,420 (0.36) 15
Tiaprofenic acid 64 (0.27) 3,299 (0.49) 600
Flurbiprofen 55 (0.23) 4,711 (0.71) 200
Tolfenamic acid 16 (0.07) 1,039 (0.16) 300
Phenylbutazone 11 (0.05) 353 (0.05) 300
Tenoxicam 8 (0.03) 225 (0.03) 20
Benzydamine 2 (0.01) 28 (0.004) 150
*The relative risks were adjusted for age (as a continuous variable), sex (as a categorical variable),
level of education (low or high), smoking status (current, previous, or never), and use or nonuse of
histamine H2-receptor antagonists, hypoglycemic medications, antihypertensive agents, and either
oral salicylates or NSAIDs. CI denotes confidence interval.
†We used a time-dependent Cox regression analysis in which nonuse served as the reference cate-
gory. Relative risks cannot be calculated on the basis of the numbers given in this table.
TABLE 3. RELATIVE RISK OF ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA 
ASSOCIATED WITH THE USE OF NSAIDS AND ORAL SALICYLATES.
DRUG AND
CUMULATIVE
EXPOSURE TIME
SUBJECTS WITH
DEMENTIA
(N=394)
ENTIRE
COHORT
(N=6989)
NO. OF
PERSON-YR RELATIVE RISK (95% CI)*
ALZHEIMER’S
DISEASE
(N=293)
VASCULAR 
DEMENTIA
(N=56)
number
NSAIDs
No exposure† 210 2553 16,715 1.00 1.00
«1 mo 88 2001 13,970 0.95 (0.70–1.29) 1.25 (0.63–2.53)
>1 to 23 mo 93 2202 15,156 0.83 (0.62–1.11) 1.36 (0.70–2.64)
»24 mo 3 233 1,654 0.20 (0.05–0.83) 0.99 (0.13–7.58)
Oral salicylates
No exposure† 252 4675 31,881 1.00 1.00
«1 mo 7 285 1,972 0.76 (0.31–1.84) —
>1 to 23 mo 93 1017 6,498 1.30 (0.97–1.74) 2.99 (1.57–5.71)
»24 mo 42 1012 7,147 0.76 (0.49–1.19) 4.88 (2.38–10.0)
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Among the subjects with two or more years of cu-
mulative use of NSAIDs, there was no significant
difference in the reduction in the risk of Alzheimer’s
disease between those taking less than one or one
defined daily dose per day (relative risk as compared
with no use, 0.17; 95 percent confidence interval, 0.02
to 1.22) and those taking more than one defined daily
dose per day (relative risk, 0.25; 95 percent confi-
dence interval, 0.03 to 1.78). There was no significant
difference in the reduction in the risk of Alzheimer’s
disease with any use between persons less than 80
years of age (relative risk as compared with no use,
0.23; 95 percent confidence interval, 0.03 to 1.71) and
persons 80 years of age or older (relative risk, 0.18; 95
percent confidence interval, 0.03 to 1.31). We used
this cutoff point because there were only 11 subjects
who already had Alzheimer’s disease before 75 years
of age. This fact relates to the high mean age at base
line of this cohort and the selection of subjects who
were free of cognitive dysfunction at the start of the
study. Because there were no subjects with at least one
apolipoprotein E e4 allele among those with long-
term cumulative use of NSAIDs, the relative risk
among such users could not be estimated. However,
among the subjects with less than 24 months but more
than 1 month of cumulative exposure to NSAIDs,
there was no significant difference in the reduction in
the risk between those with at least one apolipopro-
tein E e4 allele (relative risk as compared with no use,
0.73; 95 percent confidence interval, 0.45 to 1.19)
and those with two apolipoprotein E e3 alleles (rela-
tive risk, 0.94; 95 percent confidence interval, 0.63 to
1.40). No association was found between the risk of
Alzheimer’s disease and the use of nonnarcotic anal-
gesics or corticosteroids. Furthermore, adjustment for
the use of estrogen did not substantially alter the esti-
mates of risk in women.
DISCUSSION
In this prospective, population-based study, we
found a significantly reduced risk of Alzheimer’s dis-
ease in subjects who had taken NSAIDs for a cumu-
lative period of 24 months or more. This reduction
was not modified by age or apolipoprotein E geno-
type. The use of NSAIDs was not associated with a
reduction in the risk of vascular dementia. Our re-
sults are compatible with the hypothesis that inflam-
matory mechanisms may play a part in Alzheimer’s
disease. The results are also in line with those of some
longitudinal studies26,28 but not all.22,24,25,29,30 In the
Baltimore Longitudinal Study of Aging,26 the risk of
Alzheimer’s disease was significantly lower among
subjects who took NSAIDs for two or more years
than among nonusers. Although the results of the
latter study are in accordance with our findings, as-
sessment of drug exposure was based on extrapolated,
cross-sectional data acquired during interviews at bi-
ennial examinations. Drug-exposure data gathered this
way are probably more vulnerable to misclassification
than data from pharmacy records, especially with re-
spect to the duration of use and the doses taken.
In the current study, a cohort of subjects who were
screened and found to be free of dementia at base
line was followed for up to eight years. Since follow-
up information was almost complete, selection bias
was eliminated. The main concern regarding most pre-
vious studies of the association between NSAIDs and
the risk of Alzheimer’s disease has been the potential
for misclassification of the use of drugs. For example,
persons with preclinical dementia might more easily
forget and not report their medication history than
persons with normal cognitive function. To overcome
this potential source of information bias, we drew data
on the use of NSAIDs from pharmacy records. The
information in these pharmacy records was independ-
Figure 1. The Relative Risk of Alzheimer’s Disease in Relation to
the Cumulative Duration of NSAID Use after Base Line.
The curves were generated with the use of three quadratic
spline regressions, one without lag time, one with a lag time of
one year (meaning the exclusion from the analysis of the year
before diagnosis), and one with a lag time of two years. They
reveal a consistently decreasing risk of Alzheimer’s disease with
increasing cumulative duration of NSAID use (P for trend=0.06
for the analysis with no lag time, P for trend=0.05 for the analy-
sis with a lag time of one year, and P for trend=0.04 for the
analysis with a lag time of two years). The course of the curve
at cumulative durations of use of less than 400 days can prob-
ably be explained by misclassification of drug use, since there
were both subjects who were already using NSAIDs on a long-
term basis at base line (and for whom the precise cumulative
duration of NSAID exposure could not be calculated, because
data on drug use before base line were not available) and new
users with less than 400 days of cumulative exposure after base
line. The apparent increase in risk seen in the curve without lag
time may be explained in part by an increased use of NSAIDs
in the prodromal phase of Alzheimer’s disease. The increase in
risk disappears when a lag time is included.
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ent of characteristics such as age, sex, and cognitive
status, and thus we avoided the limitations of similar
studies in which information on the use of NSAIDs
was obtained from interviews or medical records. Un-
til 1995, NSAIDs could be obtained in the Nether-
lands only by prescription, and most over-the-counter
analgesics consist of acetaminophen, which has no
appreciable antiinflammatory properties. Moreover, in
our study, nonnarcotic analgesics other than NSAIDs
did not protect against Alzheimer’s disease. Since
1995, some NSAIDs have become available in low
doses on an over-the-counter basis. Even if the use
of over-the-counter medications led to misclassifica-
tion of NSAID exposure in our study cohort, how-
ever, this source of bias would underestimate, rather
than overestimate, a true risk reduction.
A limitation of our study is that we had no data
on the use of NSAIDs before 1991. However, since
86 percent of subjects with 24 months or more of
cumulative use were already taking NSAIDs in 1991,
it is likely that they took these drugs on a long-term
basis. Confounding by indication may explain the in-
creased risk of vascular dementia among subjects who
took platelet-inhibiting salicylates, because patients
who take these drugs for this indication may have a
higher base-line risk of vascular dementia. However,
it does not explain the reduced risk of Alzheimer’s
disease among those who took NSAIDs, since there
was no association between the presence of rheuma-
toid arthritis or osteoarthritis at base line and the risk
of Alzheimer’s disease. Another potential source of
confounding that we investigated is related to the pos-
sibility that persons with preclinical dementia may ex-
perience less pain or may communicate their pain
less clearly than unaffected persons. If they take fewer
NSAIDs, a spurious protective effect would be found.
This assumes, however, that before dementia occurs,
there is no difference in the use of NSAIDs and that
in those in whom dementia develops, the use of
NSAIDs will insidiously decrease. In our study, how-
ever, the use of NSAIDs was already lower five years
before the diagnosis of dementia, when cognitive
function was still normal. Another argument against
this potential source of confounding is the fact that
NSAIDs had no protective effect against vascular de-
mentia, whereas one might then expect that the same
direction and magnitude of confounding would have
occurred. Moreover, less use of medical care would
probably also mean that, overall, patients with de-
mentia would take fewer drugs. On the contrary, we
found a higher prevalence of overall drug use in per-
sons with dementia.
In conclusion, our results suggest that long-term
use of NSAIDs has a beneficial effect on the risk of
Alzheimer’s disease. Primary-prevention trials should
be undertaken to confirm this finding and show
whether the benefits of such therapy outweigh the
potential risks.
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